Agomab Reports Positive Phase 1 Data for AGMB-447 in IPF; Phase 2 INSPIRIA Study to Start H2 2026
AGMB sits 40% above its 52-week low of $8.75.
Summary
Positive Phase 1 data for AGMB-447 in IPF patients were reported, and the Phase 2 INSPIRIA study design was outlined, with the trial expected to start in H2 2026.
Updates
· Dow Jones Newswires — The 6mg dose had more adverse events without new safety signals. Market cap around $643M with cash runway into 2029.
Key Events · Product Development and Regulatory · AGMB
-
Positive Phase 1 Results in IPF Patients
AGMB-447 showed generally favorable safety and tolerability at 4.5 mg BID in 10 IPF patients, with no systemic safety signals; most common adverse events were cough and bronchospasm, mostly limited to inhalation.
-
Lung-Restricted PK and Target Engagement
BAL fluid levels exceeded IC90 for at least 6 hours and IC50 for 24 hours post-inhalation at 4.5 mg BID; pSMAD3 reduction in BAL cells was >50%, confirming robust ALK5 target engagement in the lung.
-
Phase 2 INSPIRIA Study Design
24-week, randomized, double-blind, placebo-controlled study in ~120 IPF patients; 2:1 randomization to AGMB-447 4 mg BID or placebo on top of standard of care; primary endpoint is change from baseline in FVC at Week 24.
-
CTA Submitted; Study Start Expected H2 2026
Clinical Trial Application for INSPIRIA has been submitted, and the company anticipates initiating the study before year-end across a large European site network.
Analysis · AGMB · Life Sciences
Positive Phase 1 results for the inhaled ALK5 inhibitor AGMB-447 in idiopathic pulmonary fibrosis (IPF) patients were announced, showing favorable safety, lung-restricted pharmacokinetics, and robust target engagement (pSMAD3 reduction >50% at 4.5 mg BID). The design of the Phase 2 INSPIRIA study was also disclosed — a 24-week, ~120-patient trial with a 2:1 randomization to 4 mg BID or placebo, using change in forced vital capacity at Week 24 as the primary endpoint. The CTA has been submitted and the study is expected to begin in the second half of 2026. This is the first clinical proof-of-mechanism for AGMB-447 in IPF patients and de-risks the program ahead of Phase 2, while also providing a clear near-term catalyst for the stock.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AGMB was trading at $12.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $643.2M. The 52-week trading range was $8.75 to $17.82. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.